A survey of college students in the United States in 2022-2023 found that around 41 percent had symptoms of depression. Symptoms of depression vary in severity and can include a loss of interest/pleas
Response and remission rates after 5 weeks of treatment in 40 depressed patients (sample 2) treated with either reboxetine (n = 20) or mirtazapine (n = 20) [33]. Patients are subdivided into COR peak
